DNA Manufacturing Market Size to Hit USD 20.28 Billion by 2032, Fueled by Gene Therapy and Synthetic Biology Growth

**DNA Manufacturing Market Size & Growth Analysis**

*Austin, Nov. 07, 2025 (GLOBE NEWSWIRE)* – According to SNS Insider, the DNA Manufacturing Market was valued at USD 5.18 billion in 2024 and is projected to reach USD 20.28 billion by 2032. This growth represents a compound annual growth rate (CAGR) of 18.65% during the period from 2025 to 2032.

The U.S. market led the industry with a valuation of USD 1.73 billion in 2024 and is expected to achieve USD 6.63 billion by 2032. This growth is driven by rising applications in gene therapy, DNA vaccines, and advanced biologic drug development.

The expansion of the DNA manufacturing sector is accelerated by the increasing adoption of cell and gene therapies, surging demand for plasmid DNA in biopharmaceutical research, and continuous innovation in synthetic biology. Strategic investments by leading biotechnology companies, coupled with supportive government policies and FDA approvals, are propelling the global market forward.

—

### Major Players in the DNA Manufacturing Market Include:
– Aldevron LLC
– Bioneer Corporation
– Catalent Inc.
– Charles River Laboratories International Inc.
– Codex DNA (Telesis Bio Inc.)
– Cytiva (Danaher Corporation)
– Eton Bioscience
– Eurofins Scientific
– GenScript Biotech Corporation
– Integrated DNA Technologies
– LGC Biosearch Technologies
– Lonza Group AG
– Quintara Biosciences
– Takara Bio Inc.
– Thermo Fisher Scientific
– Twist Bioscience
– VGXI Inc.
– WuXi Advanced Therapies

—

### DNA Manufacturing Market Segment Insights:

**By Type**
The synthetic DNA segment dominated the market share in 2024 with 71.25%, due to its extensive use in genetic engineering, synthetic biology, diagnostics, and pharmaceutical research. The plasmid DNA segment is anticipated to be the fastest-growing segment during the forecast period, driven by increased applications in cell & gene therapy, DNA vaccines, and mRNA production processes.

**By Grade**
The GMP grade segment dominated in 2024, holding a 68.50% market share. This is attributed to the rising demand for clinical-grade DNA needed in gene therapies, DNA vaccines, and other regulated therapeutic applications. The R&D Grade segment is expected to witness the fastest growth due to increased investment in early-stage research, drug discovery, and academic projects.

**By Application**
Cell & gene therapy held the largest share in 2024, accounting for 46.20% of the market, reflecting the rising clinical and commercial demand for DNA constructs used in advanced therapies. Oligonucleotide-based drugs are expected to grow at the fastest pace, fueled by an increasing focus on precision medicine and RNA-targeted drugs.

**By End-Use**
Pharmaceutical and biotechnology companies accounted for the largest share in 2024, with 60.3%. These companies are pioneers in the development and commercialization of gene therapies, DNA-based vaccines, and personalized medicines. The contract research organizations (CROs) segment is anticipated to experience the fastest growth, due to a growing number of pharmaceutical and biotech companies outsourcing DNA manufacturing to specialized partners.

—

### Regional Analysis:

– **North America** led the DNA manufacturing market with a 45.05% share in 2024. Growth in this region is driven by the booming biotechnology industry, increased investments in genetic studies, and the presence of key companies such as Thermo Fisher Scientific, Integrated DNA Technologies, and Twist Bioscience.

– The **United States** remains the dominant market, supported by a strong biotechnology ecosystem, well-established healthcare infrastructure, and significant public and private sector investments. Increasing demand for plasmid DNA in clinical-grade manufacturing and ongoing development of gene-based drugs continue to fuel robust growth.

– The **Asia Pacific** region is projected to be the fastest-growing market, with a CAGR of 19.58% through the forecast period. This surge is attributed to rising investments in life sciences, expanding biotechnology and biopharmaceutical industries, and growing demand for gene-based therapies and vaccines.

—

### Recent Developments in the DNA Manufacturing Market:

**June 2024** – *GenScript Biotech Corporation* announced the release of its newest innovation, the GenScript FLASH Gene service. This ultra-fast sequence-to-plasmid (S2P) platform meets the increasing demand for rapid, high-quality, and cost-efficient gene construct delivery, solidifying GenScript’s leading position in synthetic biology.

**June 2024** – *Thermo Fisher Scientific Inc.* launched the Thermo Scientific™ KingFisher PlasmidPro Maxi Processor—the first fully automated solution for maxi-scale plasmid DNA purification. This end-to-end automation system eliminates manual column preparation while providing high-purity plasmid DNA, enabling efficient large-scale molecular biology processes.

—

### Exclusive Report Insights:

– **Clinical Trial Utilization Trends**: Highlights regional participation and utilization rates of DNA manufacturing in clinical trials, underlining growth in North America and Europe driven by gene therapy and vaccine R&D.

– **Manufacturing Output Metrics**: Analyzes DNA production volumes by type and grade, offering insight into scalability and quality standards across global manufacturing facilities.

– **Investment and Funding Insights**: Tracks increasing biotech and pharmaceutical investments, focusing on in-house production expansion and strategic partnerships with CDMOs.

– **Workforce and Capacity Expansion Indicators**: Identifies trends in hiring, facility expansions, and infrastructure developments among leading CDMOs and CROs signaling strong capacity building.

– **Global Supply Chain Readiness**: Assesses regional manufacturing resilience, logistics capabilities, and localization efforts ensuring consistent supply of DNA products.

—

### DNA Manufacturing Market Report Scope

—

### DNA Manufacturing Market Key Segments

– **By Type:** Plasmid DNA, Synthetic DNA, Gene Synthesis, Oligonucleotide Synthesis
– **By Grade:** GMP Grade, R&D Grade
– **By Application:** Cell & Gene Therapy, Vaccines, Oligonucleotide-based Drugs, Others
– **By End Use:** Pharmaceutical and Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations

—

For more information or any custom research inquiries on the DNA Manufacturing Market, please contact us at:
📧 [email protected]

—

### About SNS Insider

SNS Insider is a leading global market research and consulting agency committed to delivering timely, accurate market data and consumer insights. Our mission is to empower clients to make confident decisions by providing comprehensive knowledge tailored to evolving market conditions through surveys, interviews, and focus groups worldwide.

—

*Buy the DNA Manufacturing Market Report Now to unlock comprehensive market insights, trends, and forecasts.*
https://www.globenewswire.com/news-release/2025/11/07/3183624/0/en/DNA-Manufacturing-Market-Size-to-Hit-USD-20-28-Billion-by-2032-Fueled-by-Gene-Therapy-and-Synthetic-Biology-Growth-SNS-Insider.html